Dessai S B, Chakraborty S, Babu Tvs, Nayanar S, Bhattacharjee A, Jones J, Balasubramanian S, Patil V M
Department of Surgical Oncology, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
Department of Radiation Oncology, Malabar Cancer Center, Malabar Cancer Center, Moozhikkara, Kodiyeri, Thalassery, Kannur, Kerala, India.
Indian J Cancer. 2016 Apr-Jun;53(2):280-283. doi: 10.4103/0019-509X.197742.
There are little data regarding safety and effectiveness of neoadjuvant chemotherapy (NACT) in patients who are considered unfit for receiving 3 weekly paclitaxel and carboplatin. The aim of this study was to study the toxicity and response rates of weekly paclitaxel and carboplatin as NACT in such cohort of patients.
Study population included advanced ovarian cancer patients who were unlikely to tolerate 3 weekly paclitaxel and carboplatin and hence received weekly paclitaxel (80 mg/m2) and carboplatin AUC-2 as NACT. The data regarding the baseline characteristics, chemotherapy tolerance, completion rates, toxicity (CTCAE version 4.02), and radiological response rates are presented. SPSS version 16 was used for analysis. Descriptive statistics is presented.
Eleven patients received this schedule. Nine patients completed nine cycles of NACT. Except one, all patients completed NACT with an average relative dose intensity of >0.8. There was no chemotherapy-related mortality. Grade 3-4 life-threatening complications were seen in two patients. The post NACT response rate was 100%.
Weekly paclitaxel and carboplatin chemotherapy is safe and efficacious in patients who are unsuitable for 3 weekly paclitaxel and carboplatin chemotherapy schedules.
关于新辅助化疗（NACT）在被认为不适合接受每3周一次紫杉醇和卡铂治疗的患者中的安全性和有效性的数据很少。本研究的目的是研究每周一次紫杉醇和卡铂作为NACT在此类患者队列中的毒性和反应率。
研究人群包括不太可能耐受每3周一次紫杉醇和卡铂的晚期卵巢癌患者，因此接受每周一次紫杉醇（80mg/m²）和卡铂AUC-2作为NACT。呈现了关于基线特征、化疗耐受性、完成率、毒性（CTCAE版本4.02）和放射学反应率的数据。使用SPSS 16版进行分析。给出描述性统计结果。
11名患者接受了该方案。9名患者完成了9个周期的NACT。除1名患者外，所有患者均完成了NACT，平均相对剂量强度>0.8。没有化疗相关的死亡。2名患者出现3-4级危及生命的并发症。NACT后的反应率为100%。
每周一次紫杉醇和卡铂化疗在不适合每3周一次紫杉醇和卡铂化疗方案的患者中是安全有效的。
